List of Excipients in Branded Drug SUMATRIPTAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	POTASSIUM PHOSPHATE, MONOBASIC
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	SODIUM HYDROXIDE
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Sandoz Inc	SUMATRIPTAN	sumatriptan	0781-6524	SULFURIC ACID

Generic Drugs Containing SUMATRIPTAN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	sumatriptan succinate	0093-2013	SODIUM CHLORIDE
Teva Pharmaceuticals USA Inc	sumatriptan succinate	0093-2013	WATER
Hikma Pharmaceuticals USA Inc	sumatriptan	0143-9638	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	sumatriptan	0143-9638	WATER

What are the Most Frequently-Used Excipients in SUMATRIPTAN?

# Of NDCs	Excipient
17	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
6	ANHYDROUS LACTOSE
4	BENZALKONIUM CHLORIDE
29	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS

Excipient Strategy for Sumatriptan

Last updated: February 25, 2026

What Are the Core Considerations in Developing an Excipient Strategy for Sumatriptan?

Sumatriptan is a selective 5-HT1B/1D receptor agonist indicated for acute migraine treatment. The excipient strategy targets ensuring bioavailability, stability, patient compliance, and manufacturability.

What Are the Pharmacokinetic and Formulation Challenges?

• Low oral bioavailability: Approximately 15%, due to extensive first-pass metabolism.
• Rapid onset: Requires fast dissolution and absorption.
• Chemical stability: Sensitive to oxidation and moisture.
• Dose flexibility: Available in 50 mg and 100 mg doses.

What Are the Typical Formulation Types for Sumatriptan?

1. Tablets: The most common oral form, requiring suitable excipients for disintegration, stability, and taste masking.
2. Injectables: For rapid onset, involve excipients that stabilize the molecule in solution, such as buffers and antioxidants.
3. Nasal sprays: Use excipients that facilitate mucoadhesion, enhance absorption, and ensure patient comfort.

What Are the Key Excipient Classes and Their Functions?

Excipient Category	Function	Examples	Rationale
Disintegrants	Promote tablet breakup in GI tract	Croscarmellose sodium, sodium starch glycolate	Fast disintegration enhances absorption
Binders	Provide tablet cohesion	Microcrystalline cellulose, povidone	Maintain tablet integrity during handling
Fillers	Achieve desired bulk	Mannitol, lactose monohydrate	Neutral properties, compatible with sumatriptan
Lubricants	Ease manufacturing	Magnesium stearate	Reduce tablet sticking and improve flow
Taste-masking agents	Improve palatability	Sucralose, flavoring agents	Enhance patient compliance
Stabilizers/Antioxidants	Prevent oxidation	Ascorbic acid, sodium bisulfite	Increase shelf life and chemical stability
Mucoadhesives (nasal formulations)	Improve absorption	Chitosan, carbopol	Enhance residence time on mucosa

How Does the Excipient Choice Impact Bioavailability and Stability?

• Bioavailability: Use of permeability enhancers (e.g., chitosan) in nasal formulations may offset poor oral absorption.
• Stability: Incorporation of antioxidants mitigates oxidation of the amine group; desiccants and moisture barriers prevent hydrolysis.
• Player comparison: Sumatriptan formulations often utilize lactose or mannitol as fillers and microcrystalline cellulose as binder, consistent across manufacturers [1].

What Are the Regulatory and Manufacturing Considerations?

• The excipient selection aligns with ICH Q3A and Q3B stability guidelines.
• Excipients must be pharmacopeia-compliant, generally recognized as safe (GRAS).
• Compatibility testing ensures excipient compatibility with sumatriptan to prevent degradation.
• For nasal formulations, excipients must avoid mucosal irritation and comply with nasal spray regulations.

How Does This Strategy Compare with Other Triptans?

• Sumatriptan's low bioavailability influences excipient choices toward rapid disintegration and absorption mechanisms.
• Other triptans (rizatriptan, zolmitriptan) have different solubility profiles and may incorporate different permeability enhancers.
• The formulary choice depends on administration route, stability, patient preference, and speed of relief.

Final Summary

Effective excipient strategy for sumatriptan integrates rapid disintegration, chemical stability, compatibility, and patient acceptability. The formulation type (tablet, nasal spray, injection) influences excipient selection. Binders, disintegrants, stabilizers, and flavoring agents play critical roles in maximizing performance. Regulatory compliance is mandatory, emphasizing excipient safety and compatibility.

---

Key Takeaways

• Sumatriptan formulations leverage disintegrants, stabilizers, and fillers to optimize bioavailability and shelf-life.
• Nasal sprays incorporate mucoadhesive agents to enhance absorption.
• Excipient compatibility and stability are crucial to drug efficacy and regulatory approval.
• Formulation choices are driven by pharmacokinetics, route of administration, and patient compliance.
• Consistent excipient selection supports manufacturing efficiency and quality control.

---

FAQs

1. Why is mannitol commonly used as an excipient in sumatriptan tablets?
   It acts as a filler and sweetener, provides a neutral pH environment, and helps improve tablet stability and palatability.

2. What role do antioxidants play in sumatriptan formulations?
   They prevent oxidation of the drug molecule, extending shelf life and maintaining chemical integrity.

3. Are taste-masking agents necessary for oral sumatriptan tablets?
   Yes, to improve palatability, especially in formulations with bitter taste profiles.

4. How do excipients in nasal formulations enhance absorption?
   They increase mucoadhesion and permeability, facilitating faster and more consistent drug delivery.

5. What considerations are important for manufacturing sumatriptan injections?
   Excipients like buffers and stabilizers must maintain drug stability in solution without causing precipitation or compatibility issues.

---

References

[1] U.S. Pharmacopeia. (2022). Sumatriptan tablets monograph. U.S. Pharmacopeia.